Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.

被引：2
|
作者：
Zhu, Viola Weijia
Bestvina, Christine M.
Lopes, Gilberto
Hamm, John Turner
Johnson, Melissa Lynne
Lammers, Philip Edward
Le, Xiuning
Marathe, Omkar
Raez, Luis E.
Rao, Suman
Sabari, Joshua K.
Scheff, Ronald J.
Tapan, Umit
Thompson, Jonathan Robert
Karachaliou, Niki
Ellers-Lenz, Barbara
Brutlach, Sabine
Smit, Egbert F.
Wu, Yi-Long
机构：
[1] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA
[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[3] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[4] Norton Canc Inst PARENT, Louisville, KY USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Baptist Canc Ctr, Memphis, TN USA
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Innovat Clin Res Inst, Anaheim, CA USA
[9] Mem Healthcare Syst, Hollywood, FL USA
[10] Medstar Franklin Sq Clin Res Ctr, Baltimore, MD USA
[11] NYU Langone Clin Canc Ctr, New York, NY USA
[12] Weill Cornell Med Coll, New York, NY USA
[13] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA
[14] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[15] Merck KGaA, Global Clin Dev, Darmstadt, Germany
[16] Merck KGaA, Dept Biostat, Darmstadt, Germany
[17] Merck KGaA, Darmstadt, Germany
[18] Netherlands Canc Inst, Amsterdam, Netherlands
[19] Guangdong Prov Peoples Hosp & Guangdong Acad Med, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS9136
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9136
引用
下载
收藏
页数：3
相关论文
共 50 条
  • [11] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
    Kim, T. M.
    Guarneri, V.
    Jye, V. P.
    Khaw, L. B.
    Yang, J. -J.
    Wislez, M.
    Huang, C.
    Kin, L. Chong
    Mazieres, J.
    Tho, L. M.
    Hayashi, H.
    Nhung, N.
    Chia, P. L.
    De Marinis, F.
    Raskin, J.
    Zhou, Q.
    Finochhiaro, G.
    Le, X.
    Tan, D.
    Brutlach, S.
    O'Brate, A.
    Adrian, S.
    Berghoff, K.
    Ellers-Lenz, B.
    Karachaliou, N.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S94 - S94
  • [12] Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib
    Tan, Daniel Shao-Weng
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Lye Mun
    Hayashi, Hidetoshi
    Nhung, Nguyen
    Chia, Puey Ling
    De Marinis, Filippo
    Le, Xiuning
    Karachaliou, Niki
    Brutlach, Sabine
    Adrian, Svenja
    Ellers-Lenz, Barbara
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [13] Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
    Piotrowska, Zofia
    Hata, Aaron N.
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2441 - 2443
  • [14] Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
    Liam, C. K.
    Ahmad, A. Rozila
    Hsia, T.
    Li, J. Y.
    Le, X.
    Heymach, J.
    Yang, J. C.
    Soo, R.
    Zhang, Y.
    Kim, S.
    Shin, S. W.
    Johne, A.
    Karachaliou, N.
    Bruns, R.
    Ellers-Lenz, B.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1118 - S1119
  • [15] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT
    Liam, Chong Kin
    Ahmad, Azura Rozila
    Hsia, Te-Chun
    Zhou, Jianying
    Kim, Dong-Wan
    Soo, Ross Andrew
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    CANCER RESEARCH, 2022, 82 (12)
  • [16] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT
    Itchins, Malinda
    Liam, Chong Kin
    Ahmad, Azura
    Hsia, Te-Chun
    Zhou, Janying
    Kim, Dong-Wan
    Soo, Ross Andrew
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 82 - 83
  • [17] Tepotinib plus osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study
    Mazieres, J.
    Kim, T. M.
    Lim, B. K.
    Wislez, M.
    Dooms, C.
    Finocchiaro, G.
    Hayashi, H.
    Liam, C. K.
    Raskin, J.
    Tho, L. M.
    de Marinis, F.
    Nadal, E.
    Smit, E.
    Le, X.
    Brutlach, S.
    Grupp, A. M. O'Brate
    Adrian, S.
    Ellers-Lenz, B.
    Karachaliou, N.
    Wu, Y. L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1419 - S1420
  • [18] Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
    Gillis, R.
    Peled, N.
    Goldshtien, I.
    Rotem, O.
    Rozenblum, A. B.
    Nechushtan, H.
    Chen, L.
    Dudnik, E.
    Zer, A.
    Yust-Katz, S.
    Shelef, I.
    Roisman, L. C.
    Inbar, E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [19] CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC
    Hui, C.
    Wakelee, H. A.
    Neal, J. W.
    Ramchandran, K. J.
    Das, M.
    Nagpal, S.
    Roy, M.
    Huang, J.
    Pollom, E.
    Myall, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E110 - E110
  • [20] Tepotinib plus Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT
    OHara, R.
    Liam, C. Kin
    Ahmad, A. Rozila
    Hsia, T. -C.
    Zhou, J.
    Kim, D. -W.
    Soo, R. Andrew
    Cheng, Y.
    Lu, S.
    Shin, S. Won
    Yang, J. Chih-Hsin
    Zhang, Y.
    Zhao, J.
    Bruns, R.
    Johne, A.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E6 - E7
12345